Login / Signup

The economic value of knowing BRCA status : BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer.

Mok OhAli McBrideSandipan BhattacharjeeMarion SlackJoanne JeterIvo Abraham
Published in: Expert review of pharmacoeconomics & outcomes research (2023)
status of all US ROC patients provides short-term and long-term evidence for optimizing treatment.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • combination therapy